

Franco Locatelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6212489/publications.pdf>

Version: 2024-02-01

366
papers

19,602
citations

11608

70
h-index

16605

123
g-index

371
all docs

371
docs citations

371
times ranked

19061
citing authors

#	ARTICLE	IF	CITATIONS
1	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2022, 139, 1785-1793.	0.6	28
2	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. <i>Journal of the National Cancer Institute</i> , 2022, 114, 436-445.	3.0	29
3	TCR α /CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders. <i>Blood Advances</i> , 2022, 6, 281-292.	2.5	22
4	Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 99.e1-99.e7.	0.6	15
5	Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 76-77.	1.5	15
6	Glucocorticoids inhibit human hematopoietic stem cell differentiation toward a common ILC precursor. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1772-1785.	1.5	5
7	Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2128-2139.	1.1	13
8	Identification of the novel HLA-B*44:532 allele, HLA-B*44:532 by next-generation sequencing. <i>Hla</i> , 2022, 99, 210-211.	0.4	3
9	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. <i>Haematologica</i> , 2022, 107, 759-764.	1.7	3
10	Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29562.	0.8	8
11	Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. <i>Cell Host and Microbe</i> , 2022, 30, 400-408.e4.	5.1	75
12	Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. <i>Blood</i> , 2022, 139, 2066-2079.	0.6	33
13	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	2.5	22
14	Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia. <i>Cancer Immunology Research</i> , 2022, 10, 291-302.	1.6	17
15	Betibeglogene Autotemcel Gene Therapy for Non α - β Genotype β -Thalassemia. <i>New England Journal of Medicine</i> , 2022, 386, 415-427.	13.9	91
16	Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29557.	0.8	5
17	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. <i>European Journal of Cancer</i> , 2022, 164, 1-17.	1.3	24
18	NK cell content does not seem to influence engraftment in ex vivo T cell depleted haploidentical stem cell transplantation. <i>Stem Cell Reports</i> , 2022, 17, 443-445.	2.3	1

#	ARTICLE	IF	CITATIONS
19	Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4. <i>Frontiers in Immunology</i> , 2022, 13, 869042.	2.2	1
20	CAPE and its synthetic derivative VP961 restore BACH1/NRF2 axis in Down Syndrome. <i>Free Radical Biology and Medicine</i> , 2022, 183, 1-13.	1.3	9
21	Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells. <i>British Journal of Haematology</i> , 2022, 197, 110-119.	1.2	10
22	Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. <i>Neuro-Oncology</i> , 2022, 24, 1150-1163.	0.6	31
23	Characterization of <i>KIR</i> ⁺ <i>NK</i> cell subsets with a monoclonal antibody selectively recognizing <i>KIR2DL1</i> and blocking the specific interaction with <i>HLA-C</i> . <i>Hla</i> , 2022, , .	0.4	5
24	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	3.3	27
25	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. <i>Leukemia</i> , 2022, 36, 1516-1524.	3.3	21
26	FGFR1 is a potential therapeutic target in neuroblastoma. <i>Cancer Cell International</i> , 2022, 22, 174.	1.8	5
27	Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29715.	0.8	10
28	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
29	HGG-46. Inter and Intra-tumor Heterogeneity of Pediatric-type Diffuse High-Grade Glioma Revealed by High-Dimensional Single-Cell Proteomics. <i>Neuro-Oncology</i> , 2022, 24, i71-i71.	0.6	1
30	MEDB-46. ONC201 affects Group 3 Medulloblastoma growth by impairing cancer stem cells. <i>Neuro-Oncology</i> , 2022, 24, i116-i116.	0.6	0
31	Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10001-10001.	0.8	15
32	Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group. <i>Biomedicines</i> , 2022, 10, 1530.	1.4	1
33	Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in <i>BRAF</i> V600 mutant pediatric low-grade glioma (pLGG).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA2002-LBA2002.	0.8	35
34	Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient. <i>Bone Marrow Transplantation</i> , 2022, 57, 1600-1603.	1.3	3
35	NK cells and ILCs in tumor immunotherapy. <i>Molecular Aspects of Medicine</i> , 2021, 80, 100870.	2.7	134
36	The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 630-634.	1.7	29

#	ARTICLE	IF	CITATIONS
37	Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention. <i>Progress in Neurobiology</i> , 2021, 196, 101892.	2.8	21
38	A literature review of 2019 novel coronavirus (SARS-CoV2) infection in neonates and children. <i>Pediatric Research</i> , 2021, 89, 1101-1108.	1.1	48
39	Downregulation of miR-326 and its host gene <i>Arrestin1</i> induces pro-survival activity of E2F1 and promotes medulloblastoma growth. <i>Molecular Oncology</i> , 2021, 15, 523-542.	2.1	8
40	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). <i>Blood</i> , 2021, 137, 1582-1590.	0.6	48
41	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β^0 -Thalassemia. <i>New England Journal of Medicine</i> , 2021, 384, 252-260.	13.9	939
42	Ethics in clinical autopsy. <i>Journal of Clinical Pathology</i> , 2021, 74, 339-343.	1.0	3
43	Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors. <i>Cancer Immunology Research</i> , 2021, 9, 170-183.	1.6	22
44	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 295-307.	0.8	163
45	The role of interferon- γ and its signaling pathway in pediatric hematological disorders. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28900.	0.8	17
46	The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment. <i>Seminars in Immunopathology</i> , 2021, 43, 101-117.	2.8	14
47	Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma. <i>Nature Communications</i> , 2021, 12, 192.	5.8	33
48	Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i> -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. <i>Journal of Clinical Oncology</i> , 2021, 39, 652-662.	0.8	41
49	HLA-haploidentical TCR $\alpha\beta^+$ /CD19 $^+$ -depleted stem cell transplantation in children and young adults with Fanconi anemia. <i>Blood Advances</i> , 2021, 5, 1333-1339.	2.5	22
50	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 843.	3.8	166
51	Monocyte macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 1157-1171.	1.2	15
52	Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants. , 2021, 9, e002293.		25
53	Recurrent genetic fusions redefine <i>MLL</i> germ line acute lymphoblastic leukemia in infants. <i>Blood</i> , 2021, 137, 1980-1984.	0.6	12
54	<i>CD56</i> , <i>HLA-DR</i> and <i>CD45</i> recognize a subtype of childhood <i>AML</i> harboring <i>CBFA2T3-GLIS2</i> fusion transcript. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 844-850.	1.1	10

#	ARTICLE	IF	CITATIONS
55	Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course. <i>Blood</i> , 2021, 138, 557-570.	0.6	26
56	Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 424.e1-424.e9.	0.6	22
57	Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. , 2021, 9, e001514.		10
58	Use of ruxolitinib to control graft-versus-hostâ€“like disease in Omenn syndrome and successfully bridging to HSCT. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2531-2533.e1.	2.0	2
59	TMOD-05. GENOME-WIDE DNA METHYLATION PROFILE: A POWERFUL STRATEGY TO RECAPITULATE HETEROGENEITY OF PEDIATRIC BRAIN TUMORS IN PRIMARY CELL LINES. <i>Neuro-Oncology</i> , 2021, 23, i36-i36.	0.6	0
60	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients â€” a 25â€“year Italian experience. <i>British Journal of Haematology</i> , 2021, 195, 278-283.	1.2	4
61	Identification of a new <i><sc>HLAâ€“</sc>*44</i> allele, <i><sc>HLAâ€“</sc>*44:02:68</i>, by next generation sequencing. <i>Hla</i> , 2021, 98, 162-163.	0.4	3
62	Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2021, 56, 2732-2741.	1.3	24
63	Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. <i>Blood Advances</i> , 2021, 5, 2901-2908.	2.5	29
64	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 385, 228-238.	13.9	209
65	The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 3790.	1.0	10
66	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. <i>Frontiers in Immunology</i> , 2021, 12, 704110.	2.2	22
67	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. <i>Blood Cancer Discovery</i> , 2021, 2, 586-599.	2.6	21
68	The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study. <i>Leukemia Research</i> , 2021, 108, 106652.	0.4	2
69	Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA. <i>Cells</i> , 2021, 10, 2541.	1.8	61
70	CD19 expression in pediatric patients with relapsed/refractory Bâ€“cell precursor acute lymphoblastic leukemia preâ€“and postâ€“treatment with blinatumomab. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29323.	0.8	8
71	MS-275 (Eentinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10671.	1.8	14
72	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. <i>Nature Medicine</i> , 2021, 27, 1806-1817.	15.2	79

#	ARTICLE	IF	CITATIONS
73	The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics. <i>IScience</i> , 2021, 24, 103350.	1.9	6
74	B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies. <i>Cells</i> , 2021, 10, 2915.	1.8	35
75	Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. <i>Blood Advances</i> , 2021, 5, 262-273.	2.5	9
76	Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. <i>Blood</i> , 2021, 138, 2383-2383.	0.6	0
77	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 1235-1235.	0.6	1
78	Outcome of Children with Wiskott-Aldrich Syndrome (WAS) Given TCR Alpha-Beta/CD19 Depleted Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Haploidentical Relative. <i>Blood</i> , 2021, 138, 1775-1775.	0.6	0
79	Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 752042.	2.2	11
80	The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency. <i>Frontiers in Immunology</i> , 2021, 12, 815404.	2.2	26
81	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 12-24.	1.3	94
82	Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. <i>Haematologica</i> , 2020, 105, 1887-1894.	1.7	33
83	Microarray expression studies on bone marrow of patients with Shwachman-Diamond syndrome in relation to deletion of the long arm of chromosome 20, other chromosome anomalies or normal karyotype. <i>Molecular Cytogenetics</i> , 2020, 13, 1.	0.4	8
84	PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 415-425.	0.9	15
85	Children and Fecal SARS-CoV-2 shedding: Just the tip of the Iceberg of Italian COVID-19 outbreak?. <i>Digestive and Liver Disease</i> , 2020, 52, 1219-1221.	0.4	8
86	Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. <i>Nature Communications</i> , 2020, 11, 5992.	5.8	87
87	Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. <i>Frontiers in Immunology</i> , 2020, 11, 610300.	2.2	149
88	Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL). <i>Frontiers in Immunology</i> , 2020, 11, 608492.	2.2	17
89	QuantiFERON®TB Gold can help clinicians in the diagnosis of haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2020, 191, e64-e67.	1.2	4
90	Phenotypic and Functional Characterization of NK Cells in $\hat{\pm}$ T-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia. <i>Cancers</i> , 2020, 12, 2187.	1.7	19

#	ARTICLE	IF	CITATIONS
91	Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML. <i>Cancers</i> , 2020, 12, 1972.	1.7	19
92	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. <i>Blood Cancer Journal</i> , 2020, 10, 77.	2.8	65
93	Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. <i>Cell Death and Disease</i> , 2020, 11, 921.	2.7	96
94	NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles. <i>Seminars in Hematology</i> , 2020, 57, 175-184.	1.8	10
95	Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition. <i>Cancers</i> , 2020, 12, 2684.	1.7	30
96	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. <i>Annals of Hematology</i> , 2020, 99, 2215-2229.	0.8	29
97	Thioridazine requires calcium influx to induce MLL-AF6 rearranged AML cell death. <i>Blood Advances</i> , 2020, 4, 4417-4429.	2.5	8
98	Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. <i>HemaSphere</i> , 2020, 4, e423.	1.2	4
99	Consensus of the Italian Primary Immunodeficiency Network on transition management from pediatric to adult care in patients affected with childhood-onset inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 967-983.	1.5	12
100	Lessons from the COVID-19 Pandemic Unique Opportunities for Unifying, Revamping and Reshaping Epidemic Preparedness of Europe's Public Health Systems. <i>International Journal of Infectious Diseases</i> , 2020, 101, 361-366.	1.5	8
101	Possible roads to improve hemophagocytic lymphohistiocytosis outcome. <i>Blood Advances</i> , 2020, 4, 6127-6129.	2.5	2
102	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy Achieving global consensus and visibility for cellular host-directed therapies. <i>International Journal of Infectious Diseases</i> , 2020, 96, 431-439.	1.5	43
103	Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. <i>New England Journal of Medicine</i> , 2020, 382, 1811-1822.	13.9	320
104	The immune system of children: the key to understanding SARS-CoV-2 susceptibility?. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 414-416.	2.7	132
105	Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. <i>Leukemia</i> , 2020, 34, 3042-3046.	3.3	13
106	Cord blood transplantation for acute leukemia. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1223-1236.	1.4	10
107	Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning Techniques. <i>Journal of Clinical Medicine</i> , 2020, 9, 1670.	1.0	4
108	Immune Modulation Properties of Zoledronic Acid on TcR β T-Lymphocytes After TcR α /CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 699.	2.2	21

#	ARTICLE	IF	CITATIONS
109	The Interplay between CD27 ^{dull} and CD27 ^{bright} B Cells Ensures the Flexibility, Stability, and Resilience of Human B Cell Memory. <i>Cell Reports</i> , 2020, 30, 2963-2977.e6.	2.9	76
110	Treosulfan+fludarabine+thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 1996-2007.	1.3	18
111	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? A multicenter EBMT-PDWP study. <i>Bone Marrow Transplantation</i> , 2020, 55, 1540-1551.	1.3	42
112	Repurposing anthelmintic agents to eradicate resistant leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 72.	2.8	3
113	Delayed referral of pediatric brain tumors during COVID-19 pandemic. <i>Neuro-Oncology</i> , 2020, 22, 1884-1886.	0.6	22
114	Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children. <i>British Journal of Haematology</i> , 2020, 189, 745-750.	1.2	12
115	Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2473-2478.	3.3	26
116	Stimuli-responsive nanoparticle-assisted immunotherapy: a new weapon against solid tumours. <i>Journal of Materials Chemistry B</i> , 2020, 8, 1823-1840.	2.9	32
117	The Pediatric Acute Leukemia Fusion Oncogene ETO2+GLIS2 Increases Self-Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells-Derived Model. <i>HemaSphere</i> , 2020, 4, e319.	1.2	8
118	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, e101-e105.	1.2	5
119	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	2.0	30
120	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	1.7	51
121	Identification of New Soluble Factors Correlated With the Development of Graft Failure After Haploidentical Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 613644.	2.2	3
122	Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. <i>Bone Marrow Transplantation</i> , 2020, 55, 1918-1927.	1.3	28
123	Modeling medulloblastoma in vivo and with human cerebellar organoids. <i>Nature Communications</i> , 2020, 11, 583.	5.8	105
124	A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study. <i>Blood</i> , 2020, 136, 8-9.	0.6	10
125	Impact of Minimal Residual Disease (MRD) Assessed before Transplantation on the Outcome of Children with Acute Myeloid Leukemia Given an Allograft: A Retrospective Study By the I-BFM Study Group. <i>Blood</i> , 2020, 136, 38-39.	0.6	1
126	Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2020, 136, 24-25.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Use of critical care resources during the first 2 weeks (February 24–March 8, 2020) of the Covid-19 outbreak in Italy. <i>Annals of Intensive Care</i> , 2020, 10, 133.	2.2	31
128	A phase I/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10535-10535.	0.8	1
129	Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R) Tj ETQq1 1 0.084314 rBT /Ove	0.8	1
130	MODL-23. DNA METHYLATION AND COPY NUMBER VARIATION PROFILE FOR CHARACTERIZATION OF PEDIATRIC BRAIN TUMOR PRIMARY CELL LINES. <i>Neuro-Oncology</i> , 2020, 22, iii415-iii415.	0.6	0
131	MBCL-18. ANALYSIS OF DNA METHYLATION PROFILES OF PEDIATRIC MEDULLOBLASTOMAS: EXPERIENCE AT THE BAMBINO GESÀ™ CHILDREN'S HOSPITAL. <i>Neuro-Oncology</i> , 2020, 22, iii391-iii392.	0.6	0
132	IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii362-iii362.	0.6	0
133	HGG-54. HISTOLOGICAL AND MOLECULAR CHARACTERIZATION OF HIGH-GRADE BRAIN TUMORS SECONDARY TO TOTAL BODY IRRADIATION FOR HEMATOLOGICAL MALIGNANCIES. <i>Neuro-Oncology</i> , 2020, 22, iii353-iii354.	0.6	0
134	Incidence and Therapeutic Implications of Germline <i>TP53</i> Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
135	Analysis of Hospitalization Events in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH) Treated with Emapalumab. <i>Blood</i> , 2020, 136, 24-24.	0.6	0
136	Response of Patients with Transfusion-Dependent β^2 -Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for β^2 -Thalassemia) Gene Therapy Based on <i>HBB</i> Genotype and Disease Genetic Modifiers. <i>Blood</i> , 2020, 136, 1-3.	0.6	1
137	Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis. <i>Blood</i> , 2020, 136, 31-32.	0.6	0
138	Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry Study. <i>Blood</i> , 2020, 136, 32-33.	0.6	0
139	Outcome of Children with Different Non-Malignant Disorders Given Allogeneic T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT). <i>Blood</i> , 2020, 136, 2-4.	0.6	0
140	Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study. <i>Blood</i> , 2020, 136, 24-25.	0.6	0
141	Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH). <i>Blood</i> , 2020, 136, 14-15.	0.6	0
142	Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 360-363.	1.2	14
143	Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27900.	0.8	6
144	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2246-2256.	0.8	186

#	ARTICLE	IF	CITATIONS
145	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. <i>Frontiers in Immunology</i> , 2019, 10, 1179.	2.2	269
146	NK Cell-Based Immunotherapy for Hematological Malignancies. <i>Journal of Clinical Medicine</i> , 2019, 8, 1702.	1.0	54
147	Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. <i>European Journal of Cancer</i> , 2019, 122, 61-71.	1.3	14
148	A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. <i>Journal of Experimental Medicine</i> , 2019, 216, 2778-2799.	4.2	132
149	TMOD-14. INNOVATIVE 3D MODEL FOR THE ESTABLISHMENT OF PRIMARY PAEDIATRIC LOW-GRADE GLIOMA (LGG) CULTURES: NEW PLATFORM FOR ADVANCED PRECLINICAL STUDIES OF INNOVATIVE AND IMMUNOTHERAPEUTIC APPROACHES. <i>Neuro-Oncology</i> , 2019, 21, ii123-ii124.	0.6	0
150	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1786-1791.	2.0	42
151	Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1970-1985.e4.	2.0	64
152	The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 132-138.	2.0	14
153	Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. <i>Haematologica</i> , 2019, 104, e543-e546.	1.7	47
154	Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies. <i>Frontiers in Immunology</i> , 2019, 10, 316.	2.2	42
155	CB2 Receptor Stimulation and Dexamethasone Restore the Anti-Inflammatory and Immune-Regulatory Properties of Mesenchymal Stromal Cells of Children with Immune Thrombocytopenia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1049.	1.8	16
156	Genomic subtyping and therapeutic targeting of acute erythroleukemia. <i>Nature Genetics</i> , 2019, 51, 694-704.	9.4	97
157	Role of interferon- β in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2019, 104, 2314-2323.	1.7	52
158	Durable remissions in <i>TCF3-HLF</i> positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. <i>Haematologica</i> , 2019, 104, e244-e247.	1.7	52
159	Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1632-1642.	1.3	25
160	Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal β Memory T Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2717.	2.2	31
161	Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia. <i>Cancer Discovery</i> , 2019, 9, 1736-1753.	7.7	37
162	Targeting Hedgehog pathway in pediatric acute myeloid leukemia: challenges and opportunities. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 87-91.	1.5	4

#	ARTICLE	IF	CITATIONS
163	Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2019, 184, 397-404.	1.2	10
164	CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. <i>British Journal of Haematology</i> , 2019, 184, 337-347.	1.2	43
165	ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. <i>Haematologica</i> , 2019, 104, 533-545.	1.7	21
166	Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2019, 134, 1294-1294.	0.6	7
167	Comparative Analysis of Alpha-Beta T-Cell and B-Cell Depleted (abTCD) HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) Versus Abtcd Haplo-HSCT with T-Cell Add-Back of Rivogenlecleucel Cell [Donor T Cells Transduced with the Inducible Caspase 9 (iC9) Gene Safety Switch] in Children with High-Risk Acute Leukemia (AL) in Remission. <i>Blood</i> , 2019, 134, 145-145.	0.6	2
168	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 3873-3873.	0.6	7
169	A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10035-10035.	0.8	4
170	Long-Term Outcome of Children with Acute Leukemia (AL) Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT). <i>Blood</i> , 2019, 134, 799-799.	0.6	0
171	Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β^2 -Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy. <i>Blood</i> , 2019, 134, 969-969.	0.6	2
172	Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. <i>Human Mutation</i> , 2018, 39, 579-587.	1.1	16
173	Hematopoietic Stem Cell Transplantation in Thalassemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 317-328.	0.9	33
174	Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1223-1231.	2.0	39
175	Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. <i>Leukemia</i> , 2018, 32, 1124-1134.	3.3	17
176	The EURECART project as a prototype model for CAR T-cell immunotherapy in Europe. <i>European Journal of Immunology</i> , 2018, 48, 216-219.	1.6	3
177	Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. <i>Oncolmmunology</i> , 2018, 7, e1433518.	2.1	120
178	Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 680-693.	1.2	44
179	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1036-1049.e5.	1.5	233
180	Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 129-143.	1.0	19

#	ARTICLE	IF	CITATIONS
181	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 799-805.	2.0	22
182	Phenotypic and functional characterization of mesenchymal stromal cells isolated from pediatric patients with severe idiopathic nephrotic syndrome. <i>Cytotherapy</i> , 2018, 20, 322-334.	0.3	6
183	Whole Genome <i>scp</i> >MBD</scp>â€seq reveals different CpG methylation patterns in Azacytidineâ€treated Juvenile Myelomonocytic Leukaemia (<scp>JMML</scp>) patients. <i>British Journal of Haematology</i> , 2018, 182, 909-912.	1.2	4
184	Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). <i>Journal of Clinical Oncology</i> , 2018, 36, 244-253.	0.8	71
185	Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP). <i>Blood Cancer Journal</i> , 2018, 8, 115.	2.8	6
186	AMBRA1 Controls Regulatory T-Cell Differentiation and Homeostasis Upstream of the FOXO3-FOXP3 Axis. <i>Developmental Cell</i> , 2018, 47, 592-607.e6.	3.1	34
187	Unrelated donor vs HLA-haploidentical \hat{I}^{\pm}/\hat{I}^2 T-cellâ€ and B-cellâ€depleted HSCT in children with acute leukemia. <i>Blood</i> , 2018, 132, 2594-2607.	0.6	101
188	Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. <i>Lancet Haematology</i> , the, 2018, 5, e450-e461.	2.2	79
189	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. <i>Blood</i> , 2018, 132, 1584-1592.	0.6	45
190	NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia. <i>Trends in Immunology</i> , 2018, 39, 577-590.	2.9	119
191	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. <i>Blood</i> , 2018, 132, 405-412.	0.6	46
192	Alpha/Beta T-Cell and B-Cell Depletion HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is an Effective Treatment for Children/Young Adults with Acute Leukemia. <i>Blood</i> , 2018, 132, 2169-2169.	0.6	1
193	CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells. <i>Blood</i> , 2018, 132, 3491-3491.	0.6	8
194	Administration of BPX-501 Cells Following \hat{A}^2 T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias. <i>Blood</i> , 2018, 132, 307-307.	0.6	8
195	Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to â‰25 years with relapsed/refractory osteosarcoma (OS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11527-11527.	0.8	22
196	Indications for Hematopoietic Stem Cell Transplantation in Children. , 2018, , 55-81.		0
197	Successful of Chemo-Free Treatment with Dasatinib and Blinatumomab in a Pediatric EBF1-PDGFR \hat{I}^2 Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 5213-5213.	0.6	3
198	Steroid-Refractory Acute Gvhd in Children: Retrospective Analysis of the AIEOP HSCT Registry. <i>Blood</i> , 2018, 132, 4578-4578.	0.6	3

#	ARTICLE	IF	CITATIONS
199	Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. <i>Nature Genetics</i> , 2017, 49, 451-456.	9.4	152
200	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. <i>British Journal of Cancer</i> , 2017, 116, 335-343.	2.9	20
201	Robot-Assisted Stereotactic Biopsy of Diffuse Intrinsic Pontine Glioma: A Single-Center Experience. <i>World Neurosurgery</i> , 2017, 101, 584-588.	0.7	50
202	Prognostic significance of flow cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. <i>British Journal of Haematology</i> , 2017, 177, 116-126.	1.2	54
203	Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. <i>Journal of Hematology and Oncology</i> , 2017, 10, 26.	6.9	34
204	MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. <i>Onc Immunology</i> , 2017, 6, e1316439.	2.1	33
205	Outcome of children with acute leukemia given HLA-haploidentical HSCT after $\hat{1}\pm\hat{1}^2$ T-cell and B-cell depletion. <i>Blood</i> , 2017, 130, 677-685.	0.6	261
206	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26664.	0.8	14
207	Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 467-474.	2.0	41
208	High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. <i>British Journal of Haematology</i> , 2017, 179, 772-780.	1.2	33
209	Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immuno-evasion. <i>Cell Reports</i> , 2017, 20, 846-853.	2.9	28
210	Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective. <i>Trends in Molecular Medicine</i> , 2017, 23, 1156-1175.	3.5	40
211	Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1126-1136.	5.1	58
212	Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol. <i>Leukemia and Lymphoma</i> , 2017, 58, 999-1001.	0.6	6
213	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017, 8, 2126.	5.8	91
214	$\hat{1}^2$ -arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells. <i>BMC Cancer</i> , 2017, 17, 488.	1.1	62
215	Loss of miR-107, miR-181c and miR-29a-3p Promote Activation of Notch2 Signaling in Pediatric High-Grade Gliomas (pHGGs). <i>International Journal of Molecular Sciences</i> , 2017, 18, 2742.	1.8	19
216	Preservation of Antigen-Specific Functions of $\hat{1}\pm\hat{1}^2$ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 332.	2.2	1

#	ARTICLE	IF	CITATIONS
217	<i>Arrestin1/miR-326 Transcription Unit Is Epigenetically Regulated in Neural Stem Cells Where It Controls Stemness and Growth Arrest. Stem Cells International, 2017, 2017, 1-11.</i>	1.2	5
218	<i>Blinatumomab use in pediatric patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from an open-label, multicenter, expanded access study.. Journal of Clinical Oncology, 2017, 35, 10530-10530.</i>	0.8	6
219	<i>Rabbit anti-human T-lymphocyte globulin and hematopoietic transplantation. Oncotarget, 2017, 8, 96460-96461.</i>	0.8	3
220	<i>Single-agent dose-finding cohort of a phase 1/2 study of lenvatinib (LEN) in children and adolescents with refractory or relapsed solid tumors.. Journal of Clinical Oncology, 2017, 35, 10544-10544.</i>	0.8	1
221	<i>MicroRNAs-Proteomic Networks Characterizing Human Medulloblastoma-SLCs. Stem Cells International, 2016, 2016, 1-10.</i>	1.2	8
222	<i>NK Cells and Other Innate Lymphoid Cells in Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2016, 7, 188.</i>	2.2	45
223	<i>MB-34CIRCULATING microRNAs IN GROUP 4 MEDULLOBLASTOMA PATIENTS. Neuro-Oncology, 2016, 18, iii104.3-iii104.</i>	0.6	1
224	<i>Human NK cells: From surface receptors to clinical applications. Immunology Letters, 2016, 178, 15-19.</i>	1.1	35
225	<i>Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. Haematologica, 2016, 101, 371-381.</i>	1.7	80
226	<i>Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016, 127, 2101-2112.</i>	0.6	208
227	<i>Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood, 2016, 127, 3424-3430.</i>	0.6	79
228	<i>Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood, 2016, 127, 1387-1397.</i>	0.6	304
229	<i>Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 4381-4389.</i>	0.8	478
230	<i>Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. British Journal of Haematology, 2016, 175, 588-601.</i>	1.2	14
231	<i>Selective Depletion of T Cells and B Cells for Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation. A Three-Year Follow-Up of Procedure Efficiency. Biology of Blood and Marrow Transplantation, 2016, 22, 2056-2064.</i>	2.0	59
232	<i>Lack of splice factor and cohesin complex mutations in pediatric myelodysplastic syndrome. Haematologica, 2016, 101, e479-e481.</i>	1.7	3
233	<i>Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation. Expert Review of Clinical Immunology, 2016, 12, 343-358.</i>	1.3	22
234	<i>Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematology, the, 2016, 3, e80-e86.</i>	2.2	95

#	ARTICLE	IF	CITATIONS
235	Human innate lymphoid cells. <i>Immunology Letters</i> , 2016, 179, 2-8.	1.1	52
236	Iron overload enhances human mesenchymal stromal cell growth and hampers matrix calcification. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 1211-1223.	1.1	24
237	Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 919-926.	0.8	111
238	Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 188-196.e4.	1.5	139
239	MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. <i>Oncotarget</i> , 2016, 7, 55395-55408.	0.8	30
240	<i>CRLF2</i> over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 59260-59272.	0.8	24
241	Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation. <i>Oncotarget</i> , 2016, 7, 82123-82138.	0.8	6
242	Mutations of <i>SETBP1</i> and <i>JAK3</i> in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. <i>Oncotarget</i> , 2016, 7, 28914-28919.	0.8	21
243	Cord blood transplantation in children with hemoglobinopathies. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1125-1136.	0.5	5
244	CD4 T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR ^{hi} /CD19+ lymphocytes. <i>Blood</i> , 2015, 125, 2349-2358.	0.6	224
245	Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. <i>Blood</i> , 2015, 125, 2311-2313.	0.6	60
246	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. <i>Blood</i> , 2015, 126, 1575-1584.	0.6	69
247	T Cell Immunotherapy for Immune Reconstitution and GVHD Prevention After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Current Stem Cell Reports</i> , 2015, 1, 206-214.	0.7	0
248	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2015, 100, 17-22.	1.7	43
249	Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing. <i>Journal of Hematology and Oncology</i> , 2015, 8, 69.	6.9	14
250	Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial. <i>British Journal of Haematology</i> , 2015, 171, 566-573.	1.2	18
251	Inhibition of Natural Killer Cell Cytotoxicity by Interleukin-6: Implications for the Pathogenesis of Macrophage Activation Syndrome. <i>Arthritis and Rheumatology</i> , 2015, 67, 3037-3046.	2.9	222
252	Acute Myeloid Leukemia in Infants: Biology and Treatment. <i>Frontiers in Pediatrics</i> , 2015, 3, 37.	0.9	45

#	ARTICLE	IF	CITATIONS
253	How I treat juvenile myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 1083-1090.	0.6	189
254	Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. <i>Haematologica</i> , 2015, 100, e99-e101.	1.7	35
255	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. <i>Haematologica</i> , 2015, 100, 315-323.	1.7	38
256	Multifunctional human CD56low CD16low natural killer cells are the prominent subset in bone marrow of both healthy pediatric donors and leukemic patients. <i>Haematologica</i> , 2015, 100, 489-498.	1.7	72
257	ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors. <i>Cancer Research</i> , 2015, 75, 824-834.	0.4	52
258	Haploidentical Haematopoietic Stem Cell Transplantation: Role of NK Cells and Effect of Cytomegalovirus Infections. <i>Current Topics in Microbiology and Immunology</i> , 2015, 395, 209-224.	0.7	13
259	Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. <i>British Journal of Haematology</i> , 2015, 170, 398-407.	1.2	34
260	Eltrombopag for treatment of thrombocytopenia-associated disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2243-2256.	0.9	16
261	Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. <i>British Journal of Haematology</i> , 2015, 169, 726-736.	1.2	68
262	Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. <i>Oncolmmunology</i> , 2015, 4, e1019981.	2.1	105
263	Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. <i>Biomarker Research</i> , 2015, 3, 13.	2.8	28
264	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	0.8	277
265	Targeting BAG-1: A novel strategy to increase drug efficacy in acute myeloid leukemia. <i>Experimental Hematology</i> , 2015, 43, 180-190.e6.	0.2	11
266	Response to comment on Multifunctional human CD56low CD16low NK cells are the prominent subset in bone marrow of both pediatric healthy donors and leukemic patients. <i>Haematologica</i> , 2015, 100, e332-3.	1.7	6
267	Febuxostat Pharmacokinetic/Pharmacodynamic Bridging from Adults to Pediatrics for Effective Prophylaxis of Tumor Lysis Syndrome: From Florence to Floret Study. <i>Blood</i> , 2015, 126, 4868-4868.	0.6	0
268	Oligophrenin-1 (OPHN1), a Gene Involved in X-Linked Intellectual Disability, Undergoes RNA Editing and Alternative Splicing during Human Brain Development. <i>PLoS ONE</i> , 2014, 9, e91351.	1.1	14
269	Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. <i>Frontiers in Immunology</i> , 2014, 5, 87.	2.2	77
270	ACUTE PROMYELOCYTIC LEUKEMIA (APL): COMPARISON BETWEEN CHILDREN AND ADULTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014032.	0.5	32

#	ARTICLE	IF	CITATIONS
271	Human Cytomegalovirus Infection Promotes Rapid Maturation of NK Cells Expressing Activating Killer Ig-like Receptor in Patients Transplanted with NKG2C ^{hi} Umbilical Cord Blood. <i>Journal of Immunology</i> , 2014, 192, 1471-1479.	0.4	176
272	<i>RASA4</i> undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. <i>Epigenetics</i> , 2014, 9, 1252-1260.	1.3	34
273	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. <i>Haematologica</i> , 2014, 99, 865-872.	1.7	77
274	Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 23-36.	0.9	69
275	HLA-haploidentical stem cell transplantation after removal of CD4 ⁺ T and B cells in children with nonmalignant disorders. <i>Blood</i> , 2014, 124, 822-826.	0.6	385
276	Farber disease in infancy resembling juvenile idiopathic arthritis: identification of two new mutations and a good early response to allogeneic haematopoietic stem cell transplantation. <i>Rheumatology</i> , 2014, 53, 1533-1534.	0.9	27
277	Autoimmune Hematological Diseases after Allogeneic Hematopoietic Stem Cell Transplantation in Children: An Italian Multicenter Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 272-278.	2.0	75
278	Natural killer cells in the treatment of high-risk acute leukaemia. <i>Seminars in Immunology</i> , 2014, 26, 173-179.	2.7	85
279	Human mesenchymal stromal cells primed with paclitaxel, apart from displaying anti-tumor activity, maintain their immune regulatory functions in vitro. <i>Cytotherapy</i> , 2014, 16, 868-870.	0.3	5
280	Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-CD4 ⁺ /CD19-depleted haploidentical stem cell grafts. <i>Journal of Translational Medicine</i> , 2014, 12, 240.	1.8	38
281	A novel self-lipid antigen targets human T cells against CD1c ⁺ leukemias. <i>Journal of Experimental Medicine</i> , 2014, 211, 1363-1377.	4.2	80
282	Large cell anaplastic medulloblastoma metastatic to the scalp: tumor and derived stem-like cells features. <i>BMC Cancer</i> , 2014, 14, 262.	1.1	14
283	HLA-Haploidentical T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Children with Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 571-576.	2.0	52
284	Extracorporeal photopheresis for paediatric patients experiencing graft-versus-host disease (GVHD). <i>Transfusion and Apheresis Science</i> , 2014, 50, 340-348.	0.5	13
285	Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. <i>Haematologica</i> , 2014, 99, 1248-1254.	1.7	57
286	Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. <i>Haematologica</i> , 2014, 99, e127-e129.	1.7	26
287	Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. <i>Blood</i> , 2014, 123, 133-140.	0.6	239
288	KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. <i>Blood</i> , 2014, 124, 2744-2747.	0.6	132

#	ARTICLE	IF	CITATIONS
289	NUP98 Fusion Proteins Are Recurrent Aberrancies in Childhood Acute Myeloid Leukemia: A Report from the AIEOP AML-2001-02 Study Group. <i>Blood</i> , 2014, 124, 1025-1025.	0.6	3
290	CRLF2 over-Expression Is a Poor Prognostic Marker in Children with High Risk T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 1071-1071.	0.6	2
291	FLT3-ITD As a Target for Minimal Residual Disease Monitoring in Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 1073-1073.	0.6	1
292	Comparison Between Related T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (TCD-Haplo) and Umbilical Cord Blood Transplantation (UCBT) in Pediatric Patients with Acute Leukemia, a Eurocord, PDWP-EBMT Study. <i>Blood</i> , 2014, 124, 1215-1215.	0.6	2
293	PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2014, 124, 1450-1450.	0.6	7
294	Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study. <i>Blood</i> , 2014, 124, 3780-3780.	0.6	1
295	Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2014, 124, 795-795.	0.6	19
296	Role of Allogeneic Hematopoietic Stem Cell Transplantation in t(4;11) Positive Acute Lymphoblastic Leukemia (ALL): A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). <i>Blood</i> , 2014, 124, 1243-1243.	0.6	0
297	Intrabone Injection of T-Cell Depleted Peripheral Blood Stem Cells from HLA-Haploidentical Donors to Reduce the Risk of Graft Rejection in Children. <i>Blood</i> , 2014, 124, 1146-1146.	0.6	0
298	Response to High Dose Imatinib and Long-Term Outcome in Children and Adolescents with Previously Untreated Chronic Myeloid Leukemia in Chronic Phase. the Italian Experience. <i>Blood</i> , 2014, 124, 1812-1812.	0.6	0
299	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMMSG). <i>Blood</i> , 2014, 124, 3670-3670.	0.6	0
300	Bone Marrow Immunophenotyping By Flow Cytometry in Refractory Cytopenia of Childhood. <i>Blood</i> , 2014, 124, 1916-1916.	0.6	0
301	Secondary Mutations of JAK3 and SETBP1 in Juvenile Myelomonocytic Leukemia and Their Propagating Capacity; A Report from the AIEOP Study Group. <i>Blood</i> , 2014, 124, 4625-4625.	0.6	0
302	At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies. <i>Journal of Leukocyte Biology</i> , 2013, 94, 1141-1157.	1.5	56
303	Negative depletion of $\hat{I}\pm/\hat{I}^2+$ T cells and of CD19+ B lymphocytes: A novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. <i>Immunology Letters</i> , 2013, 155, 21-23.	1.1	90
304	Treatment of disease recurrence after allogeneic hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia: A great challenge still to be won. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1-2.	0.8	11
305	Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. <i>Haematologica</i> , 2013, 98, 1273-1281.	1.7	30
306	Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. <i>Blood</i> , 2013, 122, 170-178.	0.6	162

#	ARTICLE	IF	CITATIONS
307	CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. <i>Blood</i> , 2013, 121, 3469-3472.	0.6	119
308	Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. <i>Blood</i> , 2013, 122, 2135-2141.	0.6	79
309	The Cannabinoid Receptor Type 2 as Mediator of Mesenchymal Stromal Cell Immunosuppressive Properties. <i>PLoS ONE</i> , 2013, 8, e80022.	1.1	33
310	Thymic function recovery after unrelated donor cord blood or T-cell depleted HLA-haploidentical stem cell transplantation correlates with leukemia relapse. <i>Frontiers in Immunology</i> , 2013, 4, 54.	2.2	51
311	Philadelphia-Like Signature In Childhood Acute Lymphoblastic Leukemia: The AIEOP Experience. <i>Blood</i> , 2013, 122, 353-353.	0.6	9
312	Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm. <i>Blood</i> , 2013, 122, 4378-4378.	0.6	10
313	DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia. <i>Oncotarget</i> , 2013, 4, 1712-1720.	0.8	23
314	Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Enrolled In The AIEOP AML 2002/01 Trial: The Impact Of Minimal Residual Disease On Patient Outcome. <i>Blood</i> , 2013, 122, 3884-3884.	0.6	14
315	Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Of The AIEOP AML 2002/01 Trial: Screening and Prognostic Impact Of cKIT Mutations. <i>Blood</i> , 2013, 122, 2655-2655.	0.6	0
316	Outcome Of Unrelated Umbilical Cord Blood Transplantation For Children With Osteopetrosis: An Eurocord and Inborn Errors Working Party (IEWP)-EBMT Study. <i>Blood</i> , 2013, 122, 2100-2100.	0.6	2
317	How I treat relapsed childhood acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 2807-2816.	0.6	263
318	Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7. <i>Blood</i> , 2012, 120, 1699-1699.	0.6	7
319	BAG1 Overexpression Restrains the Anti-Apoptotic BCL2, MCL1 and HSP70 Proteins in Acute Myeloid Leukemia.. <i>Blood</i> , 2012, 120, 2492-2492.	0.6	0
320	Molecular Aberrations in 107 Children with Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2012, 120, 2802-2802.	0.6	0
321	NOVEL Recurrent Genetic Aberrations in Pediatric AML: An AIEOP AML-2002 Study Group.. <i>Blood</i> , 2012, 120, 2494-2494.	0.6	0
322	Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. <i>Blood</i> , 2011, 117, 764-771.	0.6	218
323	Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. <i>Blood</i> , 2011, 117, 4871-4880.	0.6	94
324	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. <i>Blood</i> , 2011, 118, 2077-2084.	0.6	370

#	ARTICLE	IF	CITATIONS
325	No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. <i>Blood</i> , 2011, 118, 6683-6690.	0.6	45
326	Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4 ^{hi} Subset Dynamics and Correlates with Remission State. <i>Journal of Immunology</i> , 2011, 186, 4490-4499.	0.4	85
327	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2010, 42, 794-800.	9.4	308
328	Gene Expression-Based Classification As an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1919-1927.	0.8	74
329	Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. <i>Blood</i> , 2010, 115, 3206-3214.	0.6	685
330	Cord blood transplantation in children with haematological malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 189-196.	0.7	12
331	Impact of Minimal Residual Disease at Unrelated Cord Blood Transplantation In Children with Acute Lymphoblastic Leukemia In Remission: a Study on Behalf of Eurocord-EBMT and EBMT-PDWP. <i>Blood</i> , 2010, 116, 532-532.	0.6	1
332	Refractory Cytopenia In Childhood (RCC) with Normal Karyotype Is Unlikely to Progress to Advanced MDS Under a Watch and Wait Strategy. <i>Blood</i> , 2010, 116, 4007-4007.	0.6	6
333	Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference. <i>Clinical Immunology</i> , 2009, 133, 171-178.	1.4	76
334	Improving cord blood transplantation in children. <i>British Journal of Haematology</i> , 2009, 147, 217-226.	1.2	24
335	Germline mutation of the <i>NRAS</i> gene may be responsible for the development of juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 147, 706-709.	1.2	46
336	Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. <i>Blood</i> , 2009, 113, 3119-3129.	0.6	343
337	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. <i>Blood</i> , 2009, 114, 1859-1863.	0.6	260
338	Quantitative ultrasound detects bone impairment after bone marrow transplantation in children and adolescents affected by hematological diseases. <i>Bone</i> , 2008, 43, 177-182.	1.4	10
339	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. <i>Blood</i> , 2008, 111, 1124-1127.	0.6	33
340	Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). <i>Haematologica</i> , 2008, 93, 1694-1701.	1.7	62
341	Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. <i>Blood</i> , 2008, 111, 966-967.	0.6	60
342	Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL) Tj ETQq0 0 0 reg /Overlook 10 Tf 5	0.6	10

#	ARTICLE	IF	CITATIONS
343	Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. <i>Blood</i> , 2007, 109, 4641-4647.	0.6	126
344	Results of Unrelated Cord Blood Transplant in Fanconi Anemia Patients: Risk Factor Analysis for Engraftment and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1073-1082.	2.0	138
345	A Complex Karyotype but Not Monosomy 7 Is an Independent Prognostic Factor in Advanced Childhood MDS. <i>Blood</i> , 2007, 110, 2452-2452.	0.6	0
346	Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. <i>Blood</i> , 2006, 107, 2984-2992.	0.6	123
347	GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. <i>Blood</i> , 2005, 106, 447-453.	0.6	196
348	Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2005, 129, 622-630.	1.2	206
349	Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. <i>Blood</i> , 2005, 105, 410-419.	0.6	291
350	Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. <i>Haematologica</i> , 2004, 89, 1054-61.	1.7	22
351	Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. <i>Blood</i> , 2003, 102, 4290-4297.	0.6	160
352	Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. <i>Blood</i> , 2002, 100, 1192-1200.	0.6	201
353	Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. <i>British Journal of Haematology</i> , 2002, 116, 465-467.	1.2	116
354	Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. , 2002, 116, 465.		2
355	Incidence of, and Risk Factors for, Nosocomial Infections Among Hematopoietic Stem Cell Transplantation Recipients, With Impact on Procedure-Related Mortality. <i>Infection Control and Hospital Epidemiology</i> , 2001, 22, 510-517.	1.0	41
356	Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. <i>Blood</i> , 2001, 97, 3995-3997.	0.6	147
357	Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2001, 19, 3675-3684.	0.8	173
358	Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. <i>Transfusion</i> , 2001, 41, 1299-1305.	0.8	131
359	Method using urokinase and an antibiotic to avoid device removal in central venous catheter-related infections. <i>Medical and Pediatric Oncology</i> , 2000, 35, 434-435.	1.0	4
360	Compound heterozygosity for two different amino-acid substitution mutations in the thrombopoietin receptor (c-mpl gene) in congenital amegakaryocytic thrombocytopenia (CAMT). <i>Human Genetics</i> , 2000, 107, 225-233.	1.8	46

#	ARTICLE	IF	CITATIONS
361	Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. <i>Blood</i> , 2000, 95, 1572-1579.	0.6	153
362	Total Body Irradiation, Thiotepa, and Cyclophosphamide as a Conditioning Regimen for Children With Acute Lymphoblastic Leukemia in First or Second Remission Undergoing Bone Marrow Transplantation With HLA-Identical Siblings. <i>Journal of Clinical Oncology</i> , 1999, 17, 1838-1838.	0.8	44
363	Frequency of donor cytotoxic T cell precursors does not correlate with occurrence of acute graft-versus-host disease in children transplanted using unrelated donors. <i>Journal of Clinical Immunology</i> , 1996, 16, 107-114.	2.0	11
364	Juvenile chronic myelogenous leukemia: In vitro characterization before and after allogeneic bone marrow transplantation. <i>Medical and Pediatric Oncology</i> , 1995, 24, 166-170.	1.0	2
365	Kaposi's Sarcoma in a child after autologous bone marrow transplantation for non-Hodgkin's lymphoma. <i>Cancer</i> , 1991, 68, 1361-1364.	2.0	27
366	Rhabdomyosarcoma with Primary Osteolytic Lesions Simulating Non-Hodgkin's Lymphoma. <i>Pediatric Hematology and Oncology</i> , 1991, 8, 159-164.	0.3	7